Skip To Main Content
F Hoffmann-La Roche on Muck Rack

F Hoffmann-La Roche

As seen in: Annals of the Rheumatic Diseases, The Lancet
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with F Hoffmann-La

Contact F Hoffmann-La, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Efficacy and safety of intravenous prasinezumab in individuals with early-stage Parkinson's disease on stable symptomatic monotherapy (PADOVA): a phase 2b, multicentre, randomised, double-blind, placebo-controlled study

|
By F Hoffmann-La Roche, Judith Anzures-Cabrera, Tania Nikolcheva
| The Lancet Verified
Get full text access Log in, subscribe or purchase for full access. References 1. Tolosa, E ∙ Garrido, A ∙ Scholz, SW ∙ et al. Challenges in the diagnosis of Parkinson's disease Lancet Neurol. 2021; 20:385-397 2. Foltynie, T ∙ Bruno, V ∙ Fox, S ∙ et al. Medical, surgical, and physical treatments for Parkinson's disease Lancet. 2024; 403:305-324 3. Morris, HR ∙ Spillantini, MG ∙ Sue, CM ∙ et al. The pathogenesis of Parkinson's disease Lancet. 2024; 403:293-304 4.
Open in Who Shared Issue with article?

Deep Learning Based Quantification of Vitreous Hyperreflective Foci as a Biomarker for Intraocular Inflammation

|
By F Hoffmann-La Roche, South San Francisco, Matthew McLeod
| ophthalmologyscience.org
Introduction Drug-induced intraocular inflammation (IOI)1 is a significant adverse event commonly associated with emerging ophthalmic therapies2, particularly intravitreal injections, which are widely used for conditions such as neovascular age-related macular degeneration (nAMD)3, diabetic macular edema (DME)4, and geographic atrophy (GA)5. Drug-induced IOI is characterized by inflammation that is sterile in nature6, and the underlying pathophysiology remains incompletely understood.
Open in Who Shared Issue with article?

Tiragolumab plus atezolizumab and chemotherapy as first-line treatment for patients with unresectable oesophageal squamous cell carcinoma (SKYSCRAPER-08): a randomised, double-blind, placebo-controlled, phase 3 trial

|
By Taipei City, F Hoffmann-La Roche, Edward Cha, South San Francisco
| The Lancet Verified
Get full text access Log in, subscribe or purchase for full access. References 1. Sung, H ∙ Ferlay, J ∙ Siegel, RL ∙ et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA Cancer J Clin. 2021; 71:209-249 2. Zhu, H ∙ Ma, X ∙ Ye, T ∙ et al. Esophageal cancer in China: practice and research in the new era Int J Cancer. 2023; 152:1741-1751 3.
Open in Who Shared View Duplicates (2) Issue with article?
See all 8 licensed articles (9 Total)